I just read this e-book, simply because, according to my friend this book is written by some of the ingenious individuals who foresaw and also profited even from the financial collapse. - Sunita
I heard people are using this e-book as a Self-help guide to investing. I recently finished studying it, and never have experimented with any of the strategies; however they all appear to make sense. - Rajiv
A fantastic guide overall. Quite different from almost all other value investing publications because it concentrates on finding unique scenarios that are best to invest in. - Alexis
This particular e-book really opened up my eyes to some fresh opportunities and possibilities that while investing I should be looking for. Once you have read this traditional value investing book you will learn a lot. - Kavita
I really like the writer of this book. It is simple, properly explained, amusing, relevant, and incredibly well planned. This particular e-book is really a holy bible for dealing with unique circumstances in the market. - Saurabh

History of Nutraplus Products [Indias] Ltd.

NUTRAPLUS PRODUCTS [INDIAs] LIMITED was originally incorporated as a private limited Comp. on 6th February 1990 with the Registrar of Companies, Maharashtra at Bombay. It was subsequently converted into a Public Limited Comp. with effect from 13th June 1992 in terms of resolution passed in the Extra Ordinary General Meeting of Comp. held on 28th May 1992.

The Comp. is implementing a project for manufacture of veterinary bulk drugs namely Dimetridazole [DMZs] & Dinitolmide [DOTs] at M.I.D.C., Tarapur. Initially the Comp. proposed to set up manufacturing facilities for manufacture of Methyl Nitro Imidazole, an intermediate of DMZ with installed capacity of 240 MT per annum at a cost of Rs.123.66 Lakhs, for which it was sanctioned a term Loan of Rs.60 Lakhs from Maharashtra State Financial Corporation [MSFCs].

But now the Comp. has decided to go in for production of Dimetridazole [DMZs] & Dinitolmide [DOTs] with installed capacities of 160 MT & 300 MT respectively per annum due to high value addition in these products, than their intermediates, huge demand & export potential for these products, being veterinary bulk drugs & there being few units manufacturing these bulk drugs in the organised sector & also because these products are not under any government controls with regard to manufacturing, pricing, selling or distribution unlike other bulk drugs.